We observed several patients presenting 2-[^(18)F]FDG uptake in the reactive axillary lymph node at PET/CT imaging,ipsilateral to the site of the COVID-19 vaccine injection.Analog finding was documented at[^(18)F]Chol...We observed several patients presenting 2-[^(18)F]FDG uptake in the reactive axillary lymph node at PET/CT imaging,ipsilateral to the site of the COVID-19 vaccine injection.Analog finding was documented at[^(18)F]Choline PET/CT.The aim of our study was to describe this source of false positive cases.All patients examined by PET/CT were included in the study.Data concerning patient anamnesis,laterality,and time interval from recent COVID-19 vaccination were recorded.SUVmax was measured in all lymph nodes expressing tracer uptake after vaccination.Among 712 PET/CT scans with 2-[^(18)F]FDG,104 were submitted to vaccination;89/104 patients(85%)presented axillary and/or deltoid tracer uptake,related to recent COVID-19 vaccine administration(median from injection:11 days).The mean SUVmax of these findings was 2.1(range 1.6–3.3).Among 89 patients with false positive axillary uptake,36 subjects had received chemotherapy due to lymph node metastases from somatic cancer or lymphomas,prior to the scan:6/36 patients with lymph node metastases showed no response to therapy or progression disease.The mean SUVmax value of lymph nodal localizations of somatic cancers/lymphomas after chemotherapy was 7.8.Only 1/31 prostate cancer patients examined by[^(18)F]Choline PET/CT showed post-vaccine axillary lymph node uptake.These findings were not recorded at PET/CT scans with[^(18)F]-6-FDOPA,[^(68)Ga]Ga-DOTATOC,and[^(18)F]-fluoride.Following COVID-19 mass vaccination,a significant percentage of patients examined by 2-[^(18)F]FDG PET/CT presents axillary,reactive lymph node uptake.Anamnesis,low-dose CT,and ultrasonography facilitated correct diagnosis.Semi-quantitative assessment supported the visual analysis of PET/CT data;SUVmax values of metastatic lymph nodes were considerably higher than post-vaccine lymph nodes.[^(18)F]Choline uptake in reactive lymph node after vaccination was confirmed.After the COVID-19 pandemic,nuclear physicians need to take these potential false positive cases into account in daily clinical practice.展开更多
目的应用NEMA NU 2-2001标准测试国内部分PET/CT的性能指标。方法按照NEMA NU 2-2001标准的测试模型和方法,测试PET空间分辨率、散射系数、计数丢失和随机符合性能、灵敏度以及成像质量、衰减和散射校正精度性能指标,探讨PET/CT融合精...目的应用NEMA NU 2-2001标准测试国内部分PET/CT的性能指标。方法按照NEMA NU 2-2001标准的测试模型和方法,测试PET空间分辨率、散射系数、计数丢失和随机符合性能、灵敏度以及成像质量、衰减和散射校正精度性能指标,探讨PET/CT融合精度测试方法,并对LSO晶体PET/CT的本底计数率特性作初步测试。结果各测试指标均在厂家标称值范围内。结论采用标准的NEMA测试模型是PET性能测试的重要环节,其次是要严格控制测试模型的放射性活度,NEMA NU 2-2001标准中使用的模型或方法对于大多数使用者是可行的,可用于PET/CT安装前后的验收测试,部分测试可用于质量控制。展开更多
基金This study was approved by the Medical Ethics Committee of the“Mariano Santo”Hospital in Cosenza,Italy(CS391273).
文摘We observed several patients presenting 2-[^(18)F]FDG uptake in the reactive axillary lymph node at PET/CT imaging,ipsilateral to the site of the COVID-19 vaccine injection.Analog finding was documented at[^(18)F]Choline PET/CT.The aim of our study was to describe this source of false positive cases.All patients examined by PET/CT were included in the study.Data concerning patient anamnesis,laterality,and time interval from recent COVID-19 vaccination were recorded.SUVmax was measured in all lymph nodes expressing tracer uptake after vaccination.Among 712 PET/CT scans with 2-[^(18)F]FDG,104 were submitted to vaccination;89/104 patients(85%)presented axillary and/or deltoid tracer uptake,related to recent COVID-19 vaccine administration(median from injection:11 days).The mean SUVmax of these findings was 2.1(range 1.6–3.3).Among 89 patients with false positive axillary uptake,36 subjects had received chemotherapy due to lymph node metastases from somatic cancer or lymphomas,prior to the scan:6/36 patients with lymph node metastases showed no response to therapy or progression disease.The mean SUVmax value of lymph nodal localizations of somatic cancers/lymphomas after chemotherapy was 7.8.Only 1/31 prostate cancer patients examined by[^(18)F]Choline PET/CT showed post-vaccine axillary lymph node uptake.These findings were not recorded at PET/CT scans with[^(18)F]-6-FDOPA,[^(68)Ga]Ga-DOTATOC,and[^(18)F]-fluoride.Following COVID-19 mass vaccination,a significant percentage of patients examined by 2-[^(18)F]FDG PET/CT presents axillary,reactive lymph node uptake.Anamnesis,low-dose CT,and ultrasonography facilitated correct diagnosis.Semi-quantitative assessment supported the visual analysis of PET/CT data;SUVmax values of metastatic lymph nodes were considerably higher than post-vaccine lymph nodes.[^(18)F]Choline uptake in reactive lymph node after vaccination was confirmed.After the COVID-19 pandemic,nuclear physicians need to take these potential false positive cases into account in daily clinical practice.
文摘目的应用NEMA NU 2-2001标准测试国内部分PET/CT的性能指标。方法按照NEMA NU 2-2001标准的测试模型和方法,测试PET空间分辨率、散射系数、计数丢失和随机符合性能、灵敏度以及成像质量、衰减和散射校正精度性能指标,探讨PET/CT融合精度测试方法,并对LSO晶体PET/CT的本底计数率特性作初步测试。结果各测试指标均在厂家标称值范围内。结论采用标准的NEMA测试模型是PET性能测试的重要环节,其次是要严格控制测试模型的放射性活度,NEMA NU 2-2001标准中使用的模型或方法对于大多数使用者是可行的,可用于PET/CT安装前后的验收测试,部分测试可用于质量控制。
